A young father diagnosed with advanced Colorectal Cancer is drawing attention from the medical community after experiencing a remarkable response to an experimental immunotherapy treatment.

At just 30 years old, Spencer Laird was told his cancer had spread to his lungs and that his life expectancy could be only a few years. But after joining a clinical trial at Duke University, scans showed that many of his tumors dramatically shrank, giving new hope to patients with advanced disease.

Doctors involved in the study say the results may help researchers explore new treatment approaches for a form of colorectal cancer that has traditionally responded poorly to immunotherapy.

Table of Contents

1. Early Symptoms and Initial Diagnosis
2. Cancer Returns and Spreads to the Lungs
3. Turning to an Experimental Clinical Trial
4. Immunotherapy Shows Unexpected Results
5. Treatment Timeline and Medical Data
6. What This Means for Future Cancer Research
7. FAQ About Colorectal Cancer and Immunotherapy

Early Symptoms and Initial Diagnosis

Spencer Laird first noticed blood in his stool at age 25. At the time, the symptom was believed to be caused by hemorrhoids related to his physically demanding job as a mechanic.

About 18 months later, doctors performed a colonoscopy and diagnosed him with Colorectal Cancer.

To remove the tumor, surgeons performed an operation that removed approximately 16 inches of his colon. After recovering from surgery, Laird returned to work and spent time with his family, believing the cancer was behind him.

Cancer Returns and Spreads to the Lungs

Two years after surgery, concerns raised during a routine follow-up appointment led to additional testing. Laird’s wife noticed he had been unusually tired and insisted on further evaluation.

A full body scan revealed devastating news: the cancer had returned and spread to his lungs.

Doctors discovered 13 tumors, including one roughly the size of a golf ball. Even with treatment, physicians estimated he might have around two years to live.

The diagnosis was especially shocking for the young father, who had a wife and a young daughter at home.

Turning to an Experimental Clinical Trial

Rather than immediately starting chemotherapy, Laird and his wife began searching for alternative options. They applied to several experimental studies, eventually gaining entry into a clinical trial led by oncologist Nicholas DeVito at Duke University.

The study investigates whether immunotherapy could be used as an initial treatment for a specific type of colorectal cancer known as microsatellite stable colorectal cancer.

Typically, patients with this cancer type receive chemotherapy first, because immunotherapy has historically shown limited success in these cases.

However, the clinical trial explores whether giving immunotherapy earlier might produce stronger responses.

Immunotherapy Shows Unexpected Results

Laird joined the study in early 2025 and began receiving immunotherapy infusions every two weeks. Doctors monitored his progress with scans every six to eight weeks.

The results surprised researchers.

According to his medical team:

• The number of lung tumors decreased from 13 to 3
• The largest tumor shrank dramatically
• Remaining tumors became extremely small

The most significant tumor was reduced to only 0.6 millimeters, a fraction of its original size.

While Laird is not yet completely cancer-free, doctors say his disease is no longer considered terminal, and the treatment continues.

Treatment Timeline Overview

What This Means for Future Cancer Research

Doctors involved in the trial believe Laird’s response could represent an important step in cancer research.

Patients with microsatellite stable colorectal cancer have historically had fewer non-chemotherapy treatment options. If further research confirms these results, immunotherapy could potentially become a first-line treatment for some patients.

However, researchers caution that much more study is needed before this approach becomes standard care. Scientists are continuing to investigate which patients may benefit most from early immunotherapy and whether certain biomarkers can predict response.

Even so, the case provides valuable evidence that new treatment strategies may offer hope to people with advanced cancer.

FAQ: Colorectal Cancer and Immunotherapy

Q1: What is colorectal cancer?

Colorectal Cancer is a cancer that develops in the colon or rectum, parts of the large intestine. It is one of the most common cancers worldwide.

Q2: What is immunotherapy?

Immunotherapy is a type of cancer treatment that helps the body’s immune system recognize and attack cancer cells.

Q3: Why is this case unusual?

Many patients with microsatellite stable colorectal cancer do not respond strongly to immunotherapy. In this case, the tumors shrank dramatically after treatment.

Q4: Is immunotherapy safer than chemotherapy?

Both treatments can cause side effects. Immunotherapy often has different side effects than chemotherapy and may be better tolerated by some patients.

Q5: Is the patient cured?

The patient is not yet considered cancer-free, but the disease is currently under control and no longer considered immediately terminal.

Q6: Could this treatment become standard therapy?

Researchers say more clinical trials and long-term studies are required before early immunotherapy can become standard treatment.

A Story of Hope for Cancer Patients

For Spencer Laird, the clinical trial has allowed him to continue living life with his family while researchers learn more about how immunotherapy might transform treatment for Colorectal Cancer.

As scientists continue to explore new therapies, cases like his offer hope that future breakthroughs may change the outlook for patients facing advanced cancer.